Cytosorbents Corp (CTSO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 9,617,000 | 8,727,238 | 9,390,388 | 9,894,636 |
| Cost of goods sold | 2,803,000 | 2,519,641 | 4,108,773 | 3,391,907 |
| Gross profit | 6,814,000 | 6,207,597 | 5,281,615 | 6,502,729 |
| Research and development expense | - | - | 1,851,230 | 1,519,618 |
| Professional fees | - | - | 823,914 | 820,732 |
| Selling, general and administrative | 9,167,000 | 8,431,880 | 7,002,718 | 7,581,201 |
| Research and development, net of grant income | 1,262,000 | 1,662,925 | - | - |
| Total operating expenses | 10,429,000 | 10,094,805 | 9,677,862 | 9,921,551 |
| Loss from operations | -3,615,000 | -3,887,208 | -4,396,247 | -3,418,822 |
| Interest expense, net | -616,000 | -605,134 | -588,153 | -180,098 |
| Gain (loss) on foreign currency transactions | 6,178,000 | 3,013,984 | 2,650,309 | -544,226 |
| Total other income (expense), net | 5,562,000 | 2,408,850 | 2,062,156 | -724,324 |
| Loss before benefit from income taxes | - | -1,478,358 | -2,334,091 | -4,143,146 |
| Net income (loss) attributable to common stockholders | 1,947,000 | -1,478,358 | -2,334,091 | -4,143,146 |
| Net income (loss) available to common stockholders, basic | - | - | -2,334,091 | -4,143,146 |
| Earnings per share, basic | 0.03 | -0.02 | -0.04 | -0.08 |
| Earnings per share, diluted | 0.03 | -0.02 | -0.04 | -0.08 |
| Weighted average number of shares outstanding, basic | 62,608,598 | 60,731,929 | 54,453,006 | 54,306,041 |
| Weighted average number of shares outstanding, diluted | 67,166,377 | 60,731,929 | 54,453,006 | 54,306,041 |